TELA Bio, Inc. reported its financial results for the third quarter of 2025, revealing a revenue increase of 9% to $20.7 million compared to $18.9 million in the same period last year. For the nine months ending September 30, 2025, revenue rose 15% to $59.4 million from $51.7 million in 2024. The growth was attributed to an expanding customer base, increased international sales, and the launch of new larger-sized configurations of its OviTex PRS product line. Despite the revenue growth, the company continues to face challenges, including a net loss of $8.6 million for the quarter, down from a loss of $10.4 million in the prior year, and a total net loss of $29.8 million for the nine months, slightly up from $28.6 million in 2024.
Operationally, TELA Bio has seen a significant increase in unit sales, with OviTex units sold rising by 22% to 5,795 in the third quarter of 2025, compared to 4,767 units in the same quarter of 2024. The company also reported a gross margin of 68% for both the three and nine months ended September 30, 2025. However, the average selling prices for its hernia products decreased due to a shift in product mix towards smaller-sized units. The company’s total operating expenses decreased by 3% to $21.5 million for the quarter, driven by lower sales and marketing costs, while general and administrative expenses increased by 7% to $3.9 million.
In terms of strategic developments, TELA Bio has focused on expanding its product offerings and market presence. The company launched new configurations of its OviTex products, including the OviTex IHR Reinforced Tissue Matrix for inguinal hernia procedures, and has entered into distribution agreements to enhance its product portfolio. The company also sold its distribution rights for the NIVIS product line to MiMedx Group, resulting in an initial payment of $5 million and potential future revenue-sharing payments.
As of September 30, 2025, TELA Bio reported cash and cash equivalents of $29.7 million, down from $52.7 million at the end of 2024, and an accumulated deficit of $388.5 million. The company has secured a new credit facility of up to $70 million from Perceptive Advisors, which is expected to support its working capital needs and operational expenses. Looking ahead, TELA Bio anticipates continued investment in sales and marketing initiatives to drive growth, although it expects to incur losses in the near term as it seeks to expand its market share and product offerings.
About TELA Bio, Inc.
TELA Bio, Inc. develops innovative soft-tissue reconstruction solutions, primarily through its OviTex portfolio, which combines biologic matrices with polymer reinforcement for hernia repair and plastic surgery. Its products aim to improve clinical outcomes, reduce complications, and lower costs. The company partners with healthcare providers, leverages extensive clinical data, and holds proprietary IP to address unmet needs in tissue repair markets worldwide.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.